{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Regimen&page=39",
    "query": {
      "intervention": "Control Regimen",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 1567,
    "total_pages": 157,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Regimen&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Control+Regimen&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T07:45:40.945Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02061800",
      "title": "CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia (CML)",
        "Acute Myelogenous Leukemia (AML)",
        "Myelodysplastic Syndrome (MDS)",
        "Juvenile Myelomonocytic Leukemia (JMML)",
        "Acute Lymphoblastic Leukemia (ALL)",
        "Lymphoma (Hodgkin's and Non-Hodgkin's)"
      ],
      "interventions": [
        {
          "name": "CliniMACS CD34+ Reagent System",
          "type": "DEVICE"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Diane George",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "Up to 22 Years"
      },
      "enrollment_count": 14,
      "start_date": "2013-06-03",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2024-06-04",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02061800"
    },
    {
      "nct_id": "NCT06296836",
      "title": "Effect of Continuing Versus Holding Metformin During Hospitalizations.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Illinois Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "110 Years",
        "sex": "ALL",
        "summary": "18 Years to 110 Years"
      },
      "enrollment_count": 22,
      "start_date": "2025-01-21",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06296836"
    },
    {
      "nct_id": "NCT01346969",
      "title": "Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Reduction in Hypertrophic Skin Scarring"
      ],
      "interventions": [
        {
          "name": "EXC 001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 68,
      "start_date": "2011-06-01",
      "completion_date": "2012-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-09-09",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 12,
      "location_summary": "Pasadena, California • Whittier, California • Lake Worth, Florida + 7 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Lake Worth",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01346969"
    },
    {
      "nct_id": "NCT05048875",
      "title": "An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dengue"
      ],
      "interventions": [
        {
          "name": "Cohort 1 - Group 1 JNJ High Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 2 JNJ Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 2 JNJ Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Cohort 1 - Group 1/2 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 56,
      "start_date": "2022-02-03",
      "completion_date": "2024-09-10",
      "has_results": true,
      "last_update_posted_date": "2025-04-24",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Burlington, Vermont",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05048875"
    },
    {
      "nct_id": "NCT07348692",
      "title": "Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "PCV21 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "20vPCV licensed vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "89 Days",
        "sex": "ALL",
        "summary": "42 Days to 89 Days"
      },
      "enrollment_count": 2195,
      "start_date": "2026-01-20",
      "completion_date": "2028-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 14,
      "location_summary": "Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07348692"
    },
    {
      "nct_id": "NCT04428567",
      "title": "Treadmill Training in Fragile X-associated Tremor/Ataxia Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Fragile X Associated Tremor-ataxia Syndrome"
      ],
      "interventions": [
        {
          "name": "Dual-Task Treadmill exercise + Cognitive Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rush University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2019-07-30",
      "completion_date": "2020-03-30",
      "has_results": false,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04428567"
    },
    {
      "nct_id": "NCT05766267",
      "title": "Short-course Regimens for the Treatment of Pulmonary Tuberculosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Tuberculosis, Pulmonary",
        "Tuberculosis Infection"
      ],
      "interventions": [
        {
          "name": "Rifabutin",
          "type": "DRUG"
        },
        {
          "name": "Delamanid",
          "type": "DRUG"
        },
        {
          "name": "Bedaquiline",
          "type": "DRUG"
        },
        {
          "name": "Moxifloxacin",
          "type": "DRUG"
        },
        {
          "name": "Pyrazinamide",
          "type": "DRUG"
        },
        {
          "name": "Isoniazid",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Ethambutol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centers for Disease Control and Prevention",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "2023-11-21",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-21",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05766267"
    },
    {
      "nct_id": "NCT01335581",
      "title": "Study of Laser Treatment of Melasma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Refractory Mixed Type Melasma"
      ],
      "interventions": [
        {
          "name": "Q-Switched Nd:YAG Laser (RevLite)",
          "type": "DEVICE"
        },
        {
          "name": "Retin-A and microdermabrasion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "ConBio, a Cynosure Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2011-04",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2022-01-13",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01335581"
    },
    {
      "nct_id": "NCT00713830",
      "title": "GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Lixisenatide (AVE0010)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pen auto-injector",
          "type": "DEVICE"
        },
        {
          "name": "Sulfonylurea",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 859,
      "start_date": "2008-07",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2016-12-14",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00713830"
    },
    {
      "nct_id": "NCT03175367",
      "title": "Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evinacumab",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo",
          "type": "DRUG"
        },
        {
          "name": "Background Lipid Modifying Therapy (LMT)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 272,
      "start_date": "2017-11-10",
      "completion_date": "2020-12-14",
      "has_results": true,
      "last_update_posted_date": "2023-02-10",
      "last_synced_at": "2026-11-01T07:45:40.945Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Newport Beach, California • Boca Raton, Florida + 19 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Doral",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03175367"
    }
  ]
}